Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.We report 4-year results of the phase II randomized AtezoTRIBE study. Eligible patients with metastatic colorectal cancer (mCRC) received first-line fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI)/bevacizumab (control group, n = 73) or FOLFOXIRI/bevacizumab plus atezolizumab (experimental group, n = 145). We present overall survival (OS) and updated outcomes according to tumor immune-related biomarkers, both in the intention-To-Treat (ITT) population and the cohort of patients with proficient mismatch repair (pMMR) tumors. Median follow-up was 45.2 months (IQR, 42.6-49.2). In t

Antoniotti, C., Rossini, D., Pietrantonio, F., Salvatore, L., Lonardi, S., Tamberi, S., Marmorino, F., Moretto, R., Prisciandaro, M., Tamburini, E., Tortora, G., Passardi, A., Bergamo, F., Raimondi, A., Ritorto, G., Borelli, B., Conca, V., Ugolini, C., Aprile, G., Antonuzzo, L., Gelsomino, F., Martinelli, E., Pella, N., Masi, G., Boni, L., Galon, J., Cremolini, C., Upfront Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Bevacizumab with or Without Atezolizumab for Patients with Metastatic Colorectal Cancer: Updated and Overall Survival Results of the ATEZOTRIBE Study, <<JOURNAL OF CLINICAL ONCOLOGY>>, 2024; 42 (22): 2637-2644. [doi:10.1200/JCO.23.02728] [https://hdl.handle.net/10807/304446]

Upfront Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Bevacizumab with or Without Atezolizumab for Patients with Metastatic Colorectal Cancer: Updated and Overall Survival Results of the ATEZOTRIBE Study

Pietrantonio, Filomena;Salvatore, Lisa;Tortora, Giampaolo;
2024

Abstract

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.We report 4-year results of the phase II randomized AtezoTRIBE study. Eligible patients with metastatic colorectal cancer (mCRC) received first-line fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI)/bevacizumab (control group, n = 73) or FOLFOXIRI/bevacizumab plus atezolizumab (experimental group, n = 145). We present overall survival (OS) and updated outcomes according to tumor immune-related biomarkers, both in the intention-To-Treat (ITT) population and the cohort of patients with proficient mismatch repair (pMMR) tumors. Median follow-up was 45.2 months (IQR, 42.6-49.2). In t
2024
Inglese
Antoniotti, C., Rossini, D., Pietrantonio, F., Salvatore, L., Lonardi, S., Tamberi, S., Marmorino, F., Moretto, R., Prisciandaro, M., Tamburini, E., Tortora, G., Passardi, A., Bergamo, F., Raimondi, A., Ritorto, G., Borelli, B., Conca, V., Ugolini, C., Aprile, G., Antonuzzo, L., Gelsomino, F., Martinelli, E., Pella, N., Masi, G., Boni, L., Galon, J., Cremolini, C., Upfront Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Bevacizumab with or Without Atezolizumab for Patients with Metastatic Colorectal Cancer: Updated and Overall Survival Results of the ATEZOTRIBE Study, <<JOURNAL OF CLINICAL ONCOLOGY>>, 2024; 42 (22): 2637-2644. [doi:10.1200/JCO.23.02728] [https://hdl.handle.net/10807/304446]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/304446
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 3
social impact